Nab-paclitaxel (Nab) plus gemcitabine (G) is more effective than G alone in locally advanced, unresectable pancreatic cancer (LAUPC): The GAP trial, a GISCAD phase II comparative randomized trial
Stefano Cascinu(Vita-Salute San Raffaele University), Maria Carmela Piccirillo(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Rossana Berardi(Marche Polytechnic University), Domenica Ferrara(Ospedale San Carlo), Andrea Spallanzani(University of Modena and Reggio Emilia), Alessandro Bittoni(Marche Polytechnic University), Stefania Mosconi(Ospedale Papa Giovanni XXIII), Roberto Bianco(Federico II University Hospital), Alberto Zaniboni(Fondazione Poliambulanza Istituto Ospedaliero), Silvia Noventa(Fondazione Poliambulanza Istituto Ospedaliero), Giordano Beretta(Humanitas Gavazzeni), Alberto Morabito(University of Milan), Luigi Cavanna(University of Pavia), Roberta Marciano, Daris Ferrari, Domenico Bilancia(Azienda Ospedaliera Ospedale San Carlo Borromeo), Alberto F. Sobrero(Ospedale Policlinico San Martino), Maria Banzi(Azienda Ospedaliera S.Maria), Silvana Leo(Ospedale Vito Fazzi), Francesca Negri(University of Parma)
Cited by 4
Related Papers
Liver Transplantation for the Treatment of Small Hepatocellular Carcinomas in Patients with Cirrhosis
|New England Journal of Medicine|1996|7.1k
Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
|Annals of Oncology|2022|1.4k
FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study
|The Lancet Oncology|2015|1.1k
Initial Therapy with FOLFOXIRI and Bevacizumab for Metastatic Colorectal Cancer
|New England Journal of Medicine|2014|1.1k
Inefficacy of Immediate Node Dissection in Stage 1 Melanoma of the Limbs
|New England Journal of Medicine|1977|667